

| Número de catálogo | DV571018 |
|---|---|
| Descripción |
Dilpacimab ELISA Kit (DV571018) — Quantitative sandwich ELISA for Dilpacimab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml.
Highlights
|
| Tipo de muestra | Plasma, Serum |
| Sensibilidad | 0.156 μg/ml |
| Rango | 0.31-5 μg/mL |
| Número de acceso | Q9NR61 & P15692 |
| Aplicaciones | ELISA |
| Método de detección | Colorimetric |
| Tipo de ensayo | Quantitative |
| Recuperación | 80-120% |
| Envío | 2-8 ℃ |
| Estabilidad y almacenamiento | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Especificaciones | Dilpacimab |
| Nombres alternativos | ABT-165, PR-1283233, 1791420-09-1 |
| Fondo | Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity. |
| Nota | For Research Use Only. |

Standard Curve of Dilpacimab ELISA Kit




Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.
Correo: [email protected]


+86-027-65523339
Edificio C, No. 666, Calle Shendunsi, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский